Search results for "Lymphatic"

showing 10 items of 1179 documents

Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5-azacitidine.

2017

Myelodysplastic Syndromes are oligo-clonal stem cell disorders that are associated with cytopenias in the peripheral blood. Major causes for morbidity and mortality in myelodysplastic syndromes (MDS) patients are infections mostly due to bacteria or fungi. Beside leucopenia per se in affected patients, function of white blood cells particularly that of neutrophils seems to be impaired. Here we summarize the available data on infections in MDS patients in general and particularly those treated with 5-azacitidine.

medicine.medical_specialtyAntimetabolites AntineoplasticNeutropeniaAzacitidineInfections03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesInternal medicineGranulocyte Colony-Stimulating FactormedicineHumansIn patientMortalityInfection Controlbusiness.industryMyelodysplastic syndromesHematologyGeneral MedicineAntibiotic Prophylaxismedicine.diseasePeripheral blood030220 oncology & carcinogenesisMyelodysplastic SyndromesAzacitidineStem cellMorbiditybusiness030215 immunologymedicine.drugEuropean journal of haematology
researchProduct

Overexpression of G6PD as a model of robustness

2018

Introduction Frailty is a major geriatric syndrome that has been associated to oxidative stress. The antioxidant system is largely based on the reducing power of NADPH, whose levels are mainly determined by the enzyme glucose-6-phosphate dehydrogenase (G6PD). Material and methods Using old female Tg-mice overexpressing G6PD (18 to 26 months old), we measured frailty and different muscle parameters: oxidative stress, cross-sectional area (CSA), markers regulating protein synthesis, mitochondrial dynamics, and apoptosis. Results Our results show that 18–24 months old G6PD-Tg animals performed better in the motor coordination and grip strength test than the WT. We also found lower changes in b…

medicine.medical_specialtyAntioxidantmedicine.medical_treatment[SDV]Life Sciences [q-bio]Dehydrogenasemedicine.disease_causeBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePhysiology (medical)AdipocyteInternal medicinehemic and lymphatic diseasesmedicine030304 developmental biologychemistry.chemical_classification0303 health sciencesGlutathione3. Good healthMotor coordinationEndocrinologyEnzymechemistryApoptosis030217 neurology & neurosurgeryOxidative stress
researchProduct

Kutane Manifestationen der essentiellen Thrombozyth�mie Erythromelalgie, isch�mische Akrozyanose, Livedo racemosa*

1995

A case report is presented to illustrate the cutaneous manifestations in essential thrombocythaemia. Knowledge of the related skin lesions may lead to earlier detection of this myeloproliferative disorder. Treatment may prevent severe haemorrhagic or thrombotic complications. Erythromelalgia is causally related to thrombocythaemia; prompt relief of painful symptoms after treatment with aspirin is typical.

medicine.medical_specialtyAspirinAcrocyanosisVascular diseasebusiness.industryDermatologyLivedo racemosamedicine.diseaseDermatologyErythromelalgiahemic and lymphatic diseasesmedicinemedicine.symptomDifferential diagnosisComplicationbusinessLivedo reticularismedicine.drugDer Hautarzt
researchProduct

The inhibitors - a challenge for the management of patients with hereditary haemophilia A.

2018

Abstract Introduction. Our research strategy was aimed at evaluating the possible implication of the type of factor VIII product administered as substitution treatment to haemophilia A patients in the occurrence of inhibitors and their consequences on the management. Methods. Scientific articles from July 2015 to July 2017 were searched using the PubMed and PubMed Central databases. The used search terms included “haemophilia A”, “inhibitors”, “plasma-derived factor VIII” and “recombinant factor VIII”. Results. The risk factors for inhibitors occurrence may be patients-related (genetic and nongenetic) and treatment-related. The possibility of a correlation between the increased purity of fa…

medicine.medical_specialtyBispecific antibodyHaemophilia A030204 cardiovascular system & hematologyBioinformaticsHemophilia AFactor VIII productRecombinant factor viii03 medical and health sciences0302 clinical medicineInternal medicinehemic and lymphatic diseasesinhibitorsmedicineHumansInternal medicineFactor VIIIbusiness.industryhaemophilia amedicine.diseaseplasma-derived factor viiiRC31-1245Recombinant Proteinsneutralizing alloantibodiesSearch termsCoagulationrecombinant factor viiibusiness030215 immunologyRomanian journal of internal medicine = Revue roumaine de medecine interne
researchProduct

The influence of Kinesiology Taping on the volume of lymphoedema and manual dexterity of the upper limb in women after breast cancer treatment.

2015

The aim of our study was to evaluate the effect of Kinesiology Taping (KT) on the size of lymphoedema and manual dexterity of the upper limb in women after breast cancer treatment. We also examined whether the application of KT can replace the traditional and standard multilayered bandaging in the treatment of upper extremity lymphoedema. Group A comprised of 22 patients who underwent KT as well as pneumatic and manual lymphatic drainage. Then, group B comprised of 23 patients who were treated with quasi-KT as well as pneumatic and manual lymphatic drainage. In contrast, group C had 25 patients subjected only to the standard procedure - pneumatic and manual lymphatic drainage and multilayer…

medicine.medical_specialtyBreast NeoplasmsStandard procedureUpper Extremity03 medical and health sciencesGrip strength0302 clinical medicineBreast cancerManual lymphatic drainagemedicineHumansLymphedemaRange of Motion ArticularSurgical TapeKinesiologyHand Strengthbusiness.industryOrgan SizeMiddle Agedmedicine.diseaseSurgerybody regionsmedicine.anatomical_structureOncologyMotor Skills030220 oncology & carcinogenesisPhysical therapyUpper limbDrainagePatient evaluationFemaleRange of motionbusiness030217 neurology & neurosurgeryEuropean journal of cancer care
researchProduct

Endoscopic and surgical resection of T1a/T1b esophageal neoplasms: A systematic review

2013

AIM: To investigate potential therapeutic recommendations for endoscopic and surgical resection of T1a/T1b esophageal neoplasms. METHODS: A thorough search of electronic databases MEDLINE, Embase, Pubmed and Cochrane Library, from 1997 up to January 2011 was performed. An analysis was carried out, pooling the effects of outcomes of 4241 patients enrolled in 80 retrospective studies. For comparisons across studies, each reporting on only one endoscopic method, we used a random effects meta-regression of the log-odds of the outcome of treatment in each study. “Neural networks” as a data mining technique was employed in order to establish a prediction model of lymph node status in superficial …

medicine.medical_specialtyBrief ArticleEsophageal NeoplasmsLymphovascular invasionEndoscopic mucosal resectionRisk AssessmentRisk FactorsmedicineCarcinomaOdds RatioHumansNeoplasm InvasivenessLymph nodeNeoplasm Stagingbusiness.industryCarcinoma in situPatient SelectionCarcinomaGastroenterologyGeneral MedicineEsophageal cancermedicine.diseaseSurgerySquamous carcinomaEsophagectomymedicine.anatomical_structureTreatment OutcomeLymphatic MetastasisAdenocarcinomaRadiologyEsophagoscopyNeoplasm GradingNeoplasm Recurrence Localbusiness
researchProduct

Oral non-Hodgkin’s lymphoma in a patient with rheumatoid arthritis treated with etanercept and methotrexate

2015

Oral non-Hodgkin’s lymphomas (O-NHLs) are a rare group of diverse lymphoid tissue malignancies and represent less than 5% of the oral cavity malignancies and 2% of all extra-nodal NHLs. Oral-NHLs affect the Waldeyer’s-ring, the salivary glands, the bone of the jaws and the oral mucosa, their clinical appearance is very heterogeneous. Among the risk factors for NHLs are immunosuppression (primary or secondary), autoimmunity and inflammation. O-NHLs share the same risk factors. This case report describes a patient with O-NHL which was possibly linked to the combination of methotrexate and etanercept for the treatment of her rheumatoid arthritis. To our knowledge this is probably among the fir…

medicine.medical_specialtyCase ReportOdontologíaMalignancyEtanerceptimmune system diseaseshemic and lymphatic diseasesmedicineMedical historyOral mucosaGeneral DentistryOral Medicine and Pathologybusiness.industrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]DermatologyCiencias de la saludNon-Hodgkin's lymphomaLymphomastomatognathic diseasesmedicine.anatomical_structureRheumatoid arthritisUNESCO::CIENCIAS MÉDICASImmunologyMethotrexatebusinessmedicine.drug
researchProduct

Cationic lipide mediated transfer of c-abl and bcr antisense oligonucleotides to immature normal myeloid cells: Uptake, biological effects and modula…

1996

Uptake and biochemical and biological effects of antisense oligodeoxynucleotides (ODN) specific for c-abl and bcr genes were studied in normal immature myeloid cells. CD34-positive cells were purified by positive and negative selection and cultured in liquid culture for 7 days. These cells were then incubated with ODNs, either alone or in combination with cationic lipids. The uptake of ODNs was enhanced by the use of cationic lipids. In addition, very low concentrations of ODNs in combination with cationic lipids were capable of specifically inhibiting the expression of the c-abl gene. In contrast, no effects were seen on the expression of bcr. However, despite the effective blocking of c-a…

medicine.medical_specialtyCell Membrane PermeabilityChemical PhenomenaMolecular Sequence DataRibonuclease HAntigens CD34BiologyTransfectionPolymerase Chain ReactionCationsProto-Oncogene Proteinshemic and lymphatic diseasesInternal medicineGene expressionmedicineHumansCation Exchange ResinsRNA NeoplasmProto-Oncogene Proteins c-ablGeneCells CulturedOncogene ProteinsABLHematologyBase SequenceCell-Free SystemChemistry PhysicalCell growthCationic polymerizationbreakpoint cluster regionBiological Transporthemic and immune systemsHematologyGeneral MedicineOligonucleotides AntisenseProtein-Tyrosine Kinasesrespiratory systemHematopoietic Stem CellsLipidsMolecular biologyHaematopoiesisGene Expression RegulationDepression ChemicalLiposomesProto-Oncogene Proteins c-bcrAnnals of Hematology
researchProduct

Molecular Remission Can Be Attained in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Follicular Lymphomas after Reduced Intensity Con…

2004

Abstract RIC followed by allo-SCT is an effective salvage treatment for some relapsed hematologic malignancies due to the postulated graft versus tumour (GVT) effect. In order to evaluate the quality of the clinical response, we have investigated the molecular status of patients receiving allo-SCT for relapsed disease. Forty-four patients (19 chronic lymphocytic leukemias (CLL), 21 follicular lymphomas (FCL) and 4 small lymphocytic lymphomas (SLL)) were enrolled in a prospective phase II study. The median age was 54 years (range: 32–69 years). The median number of previous chemotherapy regimens was 2 (range: 1–5) and 23% of patients had already failed an auto-SCT. Before transplant 34% of p…

medicine.medical_specialtyChemotherapyCyclophosphamidebusiness.industrymedicine.medical_treatmentChronic lymphocytic leukemiaImmunologyCell BiologyHematologyThioTEPAmedicine.diseaseBiochemistryGastroenterologyMinimal residual diseaseSurgeryFludarabineTransplantationimmune system diseaseshemic and lymphatic diseasesInternal medicinemedicineRefractory Chronic Lymphocytic Leukemiabusinessmedicine.drugBlood
researchProduct

ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP

2020

Abstract Introduction of the nanobody caplacizumab was shown to be effective in the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in the acute setting. The official recommendations include plasma exchange (PEX), immunosuppression, and the use of caplacizumab for a minimum of 30 days after stopping daily PEX. This study was a retrospective, observational analysis of the use of caplacizumab in 60 patients from 29 medical centers in Germany. Immunosuppressive treatment led to a rapid normalization of ADAMTS13 activities (calculated median, 21 days). In 35 of 60 patients, ADAMTS13 activities started to normalize before day 30 after PEX; in 11 of 60 patients, the treatment was…

medicine.medical_specialtyClinical Trials and Observationsmedicine.medical_treatmentMedizinADAMTS13 Protein030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineVon Willebrand factorFibrinolytic AgentsInternal medicinehemic and lymphatic diseasesvon Willebrand FactormedicineHumansIn patientRetrospective StudiesAcquired Thrombotic Thrombocytopenic PurpurabiologyPurpura Thrombotic Thrombocytopenicbusiness.industryImmunosuppressionRetrospective cohort studyHematologySingle-Domain AntibodiesADAMTS13Cardiovascular and Metabolic Diseases030220 oncology & carcinogenesisbiology.proteinBiomarker (medicine)Caplacizumabbusiness
researchProduct